The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Fidelity Select Biotechnology FBIOX
- NAV / 1-Day Return 18.40 / +0.27 %
- Total Assets 4.3 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.660%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.81%
- Turnover 52%
USD | NAV as of May 31, 2024 | 1-Day Return as of May 31, 2024, 10:14 PM GMT+0
Morningstar’s Analysis FBIOX
Will FBIOX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.2
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 13.97 | 604.4 Mil | Healthcare |
Amgen Inc | 8.06 | 348.8 Mil | Healthcare |
Krystal Biotech Inc | 6.77 | 292.8 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.20 | 181.9 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.36 | 145.2 Mil | Healthcare |
Gilead Sciences Inc | 2.25 | 97.5 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 2.18 | 94.1 Mil | Healthcare |
Ascendis Pharma A/S ADR | 2.11 | 91.3 Mil | Healthcare |
UCB SA | 1.66 | 71.7 Mil | Healthcare |
Zealand Pharma A/S | 1.61 | 69.5 Mil | Healthcare |